AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
1 hedge funds and large institutions have $0 invested in AMAG Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 112 closing their positions.
99% less funds holding
Funds holding: 113 → 1 (-112)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $348M → $0 (-$348M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 112
107.44% less ownership
Funds ownership: 107.44% → 0% (-107%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$49.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$41.3M |
| 3 |
AC
Armistice Capital
New York
|
-$38.7M |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$28.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$27.1M |
AMAG Hedge Fund Activity: Q4 2020 in Review
1 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q4 2020, worth a combined $0 — down 100% from $348M a quarter earlier.
Sellers outnumbered buyers: 112 funds closed out of AMAG and 0 opened new positions — a net loss of 112 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $49.3M sold.
- 1 institutional investor held AMAG Pharmaceuticals (AMAG) as of Q4 2020, down from 113 in Q3 2020.
- Funds reported $0 of AMAG Pharmaceuticals stock for Q4 2020, down 100% quarter-over-quarter.
- 0 funds opened new AMAG Pharmaceuticals positions in Q4 2020 and 112 closed out, a net change of -112 holders.
- The largest AMAG Pharmaceuticals seller in Q4 2020 was BlackRock, an estimated $49.3M sold.
Based on aggregated 13F filings for Q4 2020.